casdatifan + midazolam

This is a **combination of casdatifan and midazolam**. Casdatifan is an orally bioavailable small-molecule inhibitor of hypoxia-inducible factor-2 alpha (HIF-2α), under development primarily for the treatment of clear cell renal cell carcinoma. Casdatifan works by inhibiting HIF-2α, leading to downstream reduction in erythropoietin and suppression of tumor hypoxia-response pathways[2]. Midazolam is a benzodiazepine, mainly used for **sedation, anxiolysis, and amnesia**, often in procedural or preanesthetic contexts. It is a positive allosteric modulator of the gamma-aminobutyric acid type A (GABAA) receptor, enhancing GABAergic inhibition in the CNS[3][4]. This combination does not represent a standard therapeutic pairing but was studied to assess pharmacodynamic and drug-drug interaction effects; notably, casdatifan was found to be a weak inducer of CYP3A4, potentially affecting the metabolism of midazolam[2].

Other names

casdatifanJNJ-63576253JNJ63576253JNJ 63576253ARC-20ARC20ARC 20midazolamVersed